Doctorado en Ciencias con Orientación en Medicina Molecular, Unidad Académica de Medicina Humana y CS, Universidad Autónoma de Zacatecas, Zacatecas 98160, Mexico.
Int J Mol Sci. 2024 Jan 26;25(3):1562. doi: 10.3390/ijms25031562.
The COVID-19 pandemic has had a significant impact on the health and economy of the global population. Even after recovery from the disease, post-COVID-19 symptoms, such as pulmonary fibrosis, continue to be a concern. This narrative review aims to address pulmonary fibrosis (PF) from various perspectives, including the fibrotic mechanisms involved in idiopathic and COVID-19-induced pulmonary fibrosis. On the other hand, we also discuss the current therapeutic drugs in use, as well as those undergoing clinical or preclinical evaluation. Additionally, this article will address various biomarkers with usefulness for PF prediction, diagnosis, treatment, prognosis, and severity assessment in order to provide better treatment strategies for patients with this disease.
COVID-19 大流行对全球人口的健康和经济造成了重大影响。即使从疾病中康复，COVID-19 后症状，如肺纤维化，仍然是一个关注点。本叙述性评论旨在从多个角度探讨肺纤维化（PF），包括特发性和 COVID-19 引起的肺纤维化中涉及的纤维化机制。另一方面，我们还讨论了目前使用的治疗药物，以及正在进行临床或临床前评估的药物。此外，本文还将讨论各种对 PF 预测、诊断、治疗、预后和严重程度评估有用的生物标志物，以为患有这种疾病的患者提供更好的治疗策略。
Zotero 插件
